Applied NeuroSolutions has inked a development deal with Eli Lilly for new drugs to treat Alzheimer's. Applied NeuroSolutions gains $2 million up front along with research funds. And it stands to earn between $10 million and $20 million for each new therapy that is developed. Applied NeuroSolutions has been investigating the proteins that gather on neurons in Alzheimer's cases.
- see this release [1] on the development deal
Related Article:
Applied NeuroSolutions appoints Ellen R. Hoffing as president and CEO. Report [2]
Links:
[1] http://www.fiercebiotech.com/node/4721
[2] http://www.fiercebiotech.com/story/c-amp-l-kirkman-tapped-to-run-biomira/2006-08-30